IP Library › Granted Patent US 11,897,862
Granted Patent B2
US 11,897,862 · App. 18/297,316 · Granted Feb 13, 2024

IKAROS zinc finger family degraders and uses thereof

Inventors: Gayatri Balan (Bellevue, WA); Peter A. Blomgren (Issaquah, WA); Chen Chen (Newark, CA); Julian A. Codelli (Mountlake Terrace, WA); Zhimin Du (Belmont, CA); Musong Kim (Bellevue, WA); Dorothée Saddier Axe (San Carlos, CA); Gregg M. Schwarzwalder (Redwood City, CA); Rhiannon Thomas-Tran (San Jose, CA); Michael T. Tudesco (Chapel Hill, NC); Chandrasekar Venkataramani (San Carlos, CA); William J. Watkins (Saratoga, CA); Brian M. Weist (Dublin, CA); Suet C. Yeung (Redmond, WA); Helen Yu (Mountain View, CA)
Assignee: Gilead Sciences, Inc.
C07D401/04C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,897,862
App. No.
18/297,316
Granted
Feb 13, 2024
Kind
B2
Abstract

The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.

Claims (11)

1. A compound of the formula:

or a pharmaceutically acceptable salt thereof.

2. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is

3. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is

4. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is

5. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is

6. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is

7. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is

8. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is

9. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is

10. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2023
From: BALAN, GAYATRI; BLOMGREN, PETER A.; CHEN, CHEN; CODELLI, JULIAN A.; DU, ZHIMIN; KIM, MUSONG; SADDIER AXE, DOROTHÉE; SCHWARZWALDER, GREGG M.; THOMAS-TRAN, RHIANNON; TUDESCO, MICHAEL T.; VENKATARAMANI, CHANDRASEKAR; WATKINS, WILLIAM J.; WEIST, BRIAN M.; YEUNG, SUET C.; YU, HELEN
To: GILEAD SCIENCES, INC.
Reel/Frame 064303/0145 →
Continuity (4)
Continuation 18184335 · Mar 15, 2023
Provisional Application 63386605 · Dec 8, 2022
Provisional Application 63321030 · Mar 17, 2022
Related Publication 20230295111A1 · Sep 21, 2023
Cited By (1)
US 12,358,887